Fulcrum Therapeutics Q4 2023 net loss $24.8M; Phase 3 REACH data expected Q4 2024

Fulcrum Therapeutics, Inc.

2023-FY EPS reported -$1.59 revenue$2,805,000

Net loss $24.8M in Q4 2023 (vs $26.1M); full-year net loss $97.3M (vs $109.9M).
Cash, equivalents, and marketable securities $236.2M; cash runway into 2026.
Phase 3 REACH trial for losmapimod in FSHD on track for topline data in Q4 2024 after enrolling 260 patients.
Phase 1b PIONEER trial for pociredir in SCD restarted; cohorts evaluating 12 mg and 20 mg daily doses.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Fulcrum Therapeutics, Inc. reported fourth quarter and full year of 2023 results: revenue $0.9 million, net income $(24.8) million.

Period: fourth quarter and full year of 2023
Revenue: $0.9 million
Net income: $(24.8) million
Result: reported results

Exact text from the filing

offering completed in January 2023 of $117.3 million, partially offset by our net cash used in operating activities in 2023. • Collaboration Revenue: Collaboration revenue was $0.9 million for the fourth quarter of 2023 as compared to $0.7 million for the fourth quarter of 2022. The increase of $0.2 million was attributable to an increase in revenues under our

View on SEC.gov

Browse all earnings releases →

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-020615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.